

Accepted Manuscript

Dual neutralization of both IL-17A and IL-17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded placebo-controlled phase 2b trial

Kim A. Papp, MD, Joseph F. Merola, MD, Alice B. Gottlieb, MD, PhD, Professor
Christopher E.M. Griffiths, MD, Nancy Cross, MD, Luke Peterson, MS, Christopher Cioffi, PhD, Andrew Blauvelt, MD

PII: S0190-9622(18)30491-2

DOI: [10.1016/j.jaad.2018.03.037](https://doi.org/10.1016/j.jaad.2018.03.037)

Reference: YMJD 12426

To appear in: *Journal of the American Academy of Dermatology*

Received Date: 5 January 2018

Revised Date: 19 March 2018

Accepted Date: 21 March 2018

Please cite this article as: Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, Cioffi C, Blauvelt A, Dual neutralization of both IL-17A and IL-17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded placebo-controlled phase 2b trial, *Journal of the American Academy of Dermatology* (2018), doi: 10.1016/j.jaad.2018.03.037.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **Dual neutralization of both IL-17A and IL-17F with bimekizumab in**
2 **patients with psoriasis: results from BE ABLE 1, a 12-week**
3 **randomized, double-blinded placebo-controlled phase 2b trial**

4 **Kim A Papp MD¹, Joseph F Merola MD², Alice B Gottlieb MD, PhD³, Professor**
5 **Christopher E M Griffiths MD⁴, Nancy Cross MD⁵, Luke Peterson MS⁵, Christopher**
6 **Cioffi PhD⁶, Andrew Blauvelt MD⁷**

7
8 *¹Probity Medical Research and K Papp Clinical Research, Waterloo, ON, Canada*

9 *²Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA*

10 *³New York Medical College, Metropolitan Hospital, New York, NY, USA*

11 *⁴Dermatology Centre, Salford Royal Hospital, University of Manchester, National Institute for*
12 *Health Research Biomedical Research Centre, Manchester, UK*

13 *⁵UCB Biosciences Inc., Raleigh, NC, USA*

14 *⁶UCB Pharma, Brussels, Belgium*

15 *⁷Oregon Medical Research Center, Portland, OR, USA*

16 **Correspondence to:** Dr Kim Papp

17 Probity Medical Research and K Papp Clinical Research, 135 Union Street East, Waterloo,
18 Ontario, Canada, N2J 1C4; Tel: +1 519 579 9535; Email: kapapp@probitymedical.com

19 **Funding:** The study was funded by UCB Pharma.

20 **Declaration of interests**

21 KAP has received consultant fees from Astellas, AstraZeneca, Baxalta, Baxter, Boehringer
22 Ingelheim, Bristol-Myers Squibb, CanFite, Celgene, Coherus, Dermira, Dow Pharma, Eli
23 Lilly, Forward Pharma, Galderma, Genentech, Janssen, Kyowa Hakko Kirin, LEO Pharma,
24 Meiji, Seika Pharma, MSD, Merck Serono, Mitsubishi Pharma, Novartis, Pfizer, Regeneron,
25 Roche, Sanofi/Genzyme, Takeda, UCB, and Valeant; investigator fees from Astellas,

Download English Version:

<https://daneshyari.com/en/article/8714894>

Download Persian Version:

<https://daneshyari.com/article/8714894>

[Daneshyari.com](https://daneshyari.com)